tbuckley/cabot-search huggingface dataset:
Medicine and the Fourth Estate
Authors: J. R. E.
Journal: Annals of Internal Medicine (1965)

Editorials1 June 1965Medicine and the Fourth EstateJ. R. E.J. R. E.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-62-6-1327 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Excerpt"The press is a mighty engine, sir."Those readers who seek occasional escape from the real tensions of the twentieth century by excursion into the fictional throes of the nineteenth will recognize the above weighty words as those spoken to Mr. Pickwick, on the occasion of his visit to observe a local parliamentary election, by Editor Pott of theEatanswill Gazette(1). Such readers will also recall the devastating effect on Mr. Harding, the kindly and sensitive clergyman-warden of Hiram's Hospital for old men, of the editorial attack on his sinecure and his motives by the dailyJupiter—as told by...References1. DICKENS C: The Posthumous Papers of the Pickwick Club, 1836-37, Chap. 13. Google Scholar2. TROLLOPE A: The Warden, 1855. Google Scholar3. ELKINTON JR: Editorial: Moral problems in the use of borrowed organs, artificial and transplanted. Ann. Intern. Med. 60: 309, 1964. LinkGoogle Scholar4. Letters and comments: Moral problems of artificial and transplanted organs. Ann. Intern. Med. 61: 355, 1964. LinkGoogle Scholar5. ELKINTON JR: Editorial: Hemodialysis for chronic renal failure. Ann. Intern. Med. 62: 621, 1965. LinkGoogle Scholar6. Communications and Medical Research: Proceedings of a National Symposium held October 17, 1963, sponsored by the University of Pennsylvania. Printing Office of the University of Pennsylvania, Philadelphia, 1964. Google Scholar7. GRISWOLD EN: Responsibility of the legal profession. Harvard Today, 9, Jan., 1965. Google Scholar8. BERTIN L: Letter: Science writing. Canad. Med. Ass. J. 91: 1373, 1964. MedlineGoogle Scholar9. Editorials: Science writing. Ibid., pp. 977, 1077, 1127. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Note: This editorial is based on a talk given by the Editor to the National Association of Science Writers in Chicago, March 23, 1965. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1965Volume 62, Issue 6Page: 1327-1330 ePublished: 1 December 2008 Issue Published: 1 June 1965 PDF downloadLoading ...
A multiplex assay for detection of common pediatric sarcoma tumor markers
Authors: R. A. Bender, J. Y. Liu, H. Li, K. Z. Qu, A. D. Sferruzza, H. R. Sanders
Journal: Journal of Clinical Oncology (2007)

10041 Background: Molecular assays for tumor markers have become an important component in diagnosing pediatric sarcomas and small round cell tumors. We developed a multiplex assay to detect 7 common translocations associated with synovial sarcoma (SYT/SSX1, SYT/SSX2), Ewing's sarcoma (EWS/FLI1, EWS/ERG), rhabdomyosarcoma (PAX3/FKHR, PAX7/FKHR), and small round cell desmoplastic tumors (SRCDT) (EWS/WT1). Methods: 27 samples were analyzed with the multiplex assay: 13 formalin-fixed paraffin-embedded tumor samples, 5 fresh frozen tumor samples, 2 commercial RNA samples (SYT/SSX1, SYT/SSX2), 3 cell line samples (EWS/FLI, EWS/ERG, PAX3/FKHR), 1 synthetic control (PAX7/FKHR), and 3 negative controls. After RNA extraction, RT-PCR was performed using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA). 12 primers were added to a single master mix to amplify all 7 translocations and an internal control; 1 primer from each pair was fluorescently labeled. After RT-PCR, the PCR products were separated on a genetic analyzer and the translocations identified based on the size of the PCR products and their signal intensity. Samples were also analyzed by our current assay (real-time RT-PCR or standard RT-PCR/gel electrophoresis). Results: The results of our current and multiplex assays were positive for all synthetic controls, cell lines, and commercial RNA samples and were concordant for 15/18 tumor samples: 2/7 synovial sarcoma samples were positive for SYT/SSX1 and 3/7 for SYT/SSX2; 2/6 Ewing's sarcoma samples were EWS/FLI1-positive; 1/1 SRCDT sample was EWS/WT1-positive; and 4/4 rhabdomyosarcoma samples were negative. The 3 discordant samples tested negative with our current assay; the new multiplex assay detected EWS/FLI1 in 1 of these and SYT/SSX2 in 2, in agreement with the histological classification. Conclusions: This multiplex assay can detect 7 translocations commonly found in pediatric soft tissue tumors in a single-tube reaction, with increased clinical sensitivity relative to our current methods. No significant financial relationships to disclose.
Performance status versus anatomical recovery in metastatic disease: The role of palliative radiation treatment
Authors: Alfonso Reginelli, Giustino Silvestro, Giovanni Fontanella, Angelo Sangiovanni, Mario Conte, Iolanda Nuzzo, Ada Di lecce, Antonia Martino, Roberta Grassi, Paola Murino, Salvatore Cappabianca
Journal: International Journal of Surgery (2016)
Detailed Lymph Node Sectioning of Papillary Thyroid Carcinoma Specimen Increases the Number of pN1a Patients
Authors: Felix Haglund, Stina Garvin, Catharina Ihre-Lundgren, Inga-Lena Nilsson, Evelina Hall, Tobias Carling, Anders Höög, C. Christofer Juhlin
Journal: Endocrine Pathology (2016)
Siglec-H protects from virus-triggered severe systemic autoimmunity
Authors: Heike Schmitt, Sabrina Sell, Julia Koch, Martina Seefried, Sophia Sonnewald, Christoph Daniel, Thomas H. Winkler, Lars Nitschke
Journal: The Journal of Experimental Medicine (2016)

It is controversial whether virus infections can contribute to the development of autoimmune diseases. Type I interferons (IFNs) are critical antiviral cytokines during virus infections and have also been implicated in the pathogenesis of systemic lupus erythematosus. Type I IFN is mainly produced by plasmacytoid dendritic cells (pDCs). The secretion of type I IFN of pDCs is modulated by Siglec-H, a DAP12-associated receptor on pDCs. In this study, we show that Siglec-H–deficient pDCs produce more of the type I IFN, IFN-α, in vitro and that Siglec-H knockout (KO) mice produce more IFN-α after murine cytomegalovirus (mCMV) infection in vivo. This did not impact control of viral replication. Remarkably, several weeks after a single mCMV infection, Siglec-H KO mice developed a severe form of systemic lupus–like autoimmune disease with strong kidney nephritis. In contrast, uninfected aging Siglec-H KO mice developed a mild form of systemic autoimmunity. The induction of systemic autoimmune disease after virus infection in Siglec-H KO mice was accompanied by a type I IFN signature and fully dependent on type I IFN signaling. These results show that Siglec-H normally serves as a modulator of type I IFN responses after infection with a persistent virus and thereby prevents induction of autoimmune disease.
P-147 Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment
Authors: S. Yuki, Y. Komatsu, H. Nakatsumi, Y. Kawamoto, T. Muranaka, K. Sawada, Y. Tsuji, A. Hosokawa, M. Nakamura, O. Muto, T. Sasaki, I. Iwanaga, K. Hatanaka, A. Sato, K. Eto, K. Furukawa, M. Tateyama, Y. Takahashi, S. Sogabe, T. Honda, N. Sakamoto, Y. Sakata
Journal: Annals of Oncology (2016)
Diagnosis of pneumothorax without exposure to ionising radiation
Authors: Rosa Maria Ammendola, Giovanni Barchetti, Isabella Ceravolo, Andrea Fiorelli, Iacopo Carbone
Journal: Thorax (2016)

A 14-year-old female patient affected by ataxia telangiectasia (AT) syndrome presented with mild dyspnoea and chest discomfort of a few days duration. After a short course of antibiotic therapy, which yielded no significant clinical improvement, a chest MRI was requested to evaluate possible acute or chronic pulmonary infections. The choice fell on MRI first because the patient’s conditions was not critical, and, second, to avoid further exposure to ionising radiations, as the patient had undergone a chest X-ray 2 weeks earlier for a similar episode.

The MRI study unexpectedly revealed a spontaneous right-sided pneumothorax of moderate size (figure 1). The pneumothorax was successfully treated with a chest tube and the patient recovered …
Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.
Authors: Tarik Salman, Ahmet Bilici, Cagatay Arslan, Umut Varol, Ibrahim Yildiz, Murat Akyol, Yasar Yildiz, Yuksel Kucukzeybek, Ahmet Alacacioglu, Ugur Yilmaz
Journal: Journal of Clinical Oncology (2016)

615 Background: Thromboembolism is common in cancer patients.Thrombin activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and prothrombin fragment 1+2 (F1+2) are newly identified molecules involved in coagulation and fibrinolysis. The aim of this study was to investigate the relationship between clinicopathologic characteristics and TAFI, TFPI and F1+2 levels in patients with advanced colorectal cancer. Methods: Eighty-two patients (32 metastatic, 50 locally advanced disease) diagnosed with colorectal cancer in the medical oncology clinic, without history of thromboembolism, had not undergone an intervention, and not on medication affecting coagulation were included in the study. Serum TAFI, TFPI, and prothrombin F1+2 levels were evaluated via enzyme-linked immunosorbent assay. Clinicopathologic characteristics of the patients were investigated retrospectively from the medical records of the patients. Results: The plasma TAFI, TFPI, and prothrombin F1+2 levels were high in 70, 71, and 96% of the patients, respectively. Prothrombin F1+2 levels were higher among patients with lower performance scores. TFPI levels were higher among patients with tumor grades of 2 and 3. TAFI levels were higher among rectal cancer cases. Conclusions: There is an association between tumor grade and coagulation cascade. The higher prothrombin F1+2 levels, an indicator of active coagulation cascade, among patients with low performance scores may indicate that the coagulation cascade of these patients is more active. Higher TAFI levels among rectal cancer patients may be related to the natural course of the disease
Surgical Treatment of Epilepsy
Authors: C E Elger, J Schramm
Journal: BMJ (1964)

Twenty percent of the approximately 800,000 epileptic patients in Germany cannot be treated adequately by pharmacotherapy alone. According to conservative estimates, epilepsy surgery could be of fundamental therapeutic benefit to at least 10-25% of these patients. A complex presurgical diagnostic program is the basis for any epilepsy surgery. Numerous methods are used to create a hypothesis about the location and size of the epileptogenic area. In addition, before surgery is performed, it must be established that no additional serious neurological or neuropsychological deficits will result from the planned resection. For this purpose, electrostimulation of the cortex and temporary anaesthesia of brain areas by amobarbital tests are performed. In intractable epilepsy originating in the temporal lobe about 60% of patients become seizure free after surgery. Another 15-20% benefit from surgery by a significant improvement in their seizure situation. Resections of the dominant temporal lobe result in further impairment of memory functions in about 20-30% of patients.
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2
Authors: Satoshi Inoue, Wanda Y. Li, Alan Tseng, Isabel Beerman, Andrew J. Elia, Sean C. Bendall, François Lemonnier, Ken J. Kron, David W. Cescon, Zhenyue Hao, Evan F. Lind, Naoya Takayama, Aline C. Planello, Shu Yi Shen, Alan H. Shih, Dana M. Larsen, Qinxi Li, Bryan E. Snow, Andrew Wakeham, Jillian Haight, Chiara Gorrini, Christian Bassi, Kelsie L. Thu, Kiichi Murakami, Alisha R. Elford, Takeshi Ueda, Kimberly Straley, Katharine E. Yen, Gerry Melino, Luisa Cimmino, Iannis Aifantis, Ross L. Levine, Daniel D. De Carvalho, Mathieu Lupien, Derrick J. Rossi, Garry P. Nolan, Rob A. Cairns, Tak W. Mak
Journal: Cancer Cell (2016)
BMA annual meeting: Unmanageable workload is pushing GPs to go part time, GP leader warns
Authors: Abi Rimmer
Journal: BMJ (2016)

An unmanageable workload in general practice is pushing GPs to work part time, the BMA’s GP committee leader has warned.

Speaking at the BMA’s annual representatives meeting in Belfast on Wednesday 22 June, Chaand Nagpaul warned that GPs were struggling under increased workforce pressures.

“Unmanageable workload is fuelling GPs turning to part time work, with one in five intending to reduce clinical sessions further,” he said. “Making the job …
Transplantable Tumors off the Syrian Golden Hamster (&lt;italic&gt;Mesocricetus auratus&lt;/italic&gt;)&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;4&lt;/xref&gt;
Authors: Humberto Garcia, Carlo Baroni, Henry Rappaport
Journal: JNCI Journal of the National Cancer Institute (1961)

The biological behavior and morphological features of 8 transplantable tumors of the Syrian golden hamster are described. Included are a 20-carcinoma of the breast, an N-2-methylcholanthrene-induced adenofluorenylacetamide induced bile-duct carcinoma, and a cellular blue nevus-like melanotic tumor induced by the cutaneous application of 7,12-dimethylbenz[a]anthracene (DMBA). Five additional neoplasms, a plasmacytoma, a fibromyxosarcoma, a malignant neurilemmoma, a cutaneous adnexal cystadenocarcinoma, and a malignant hemangiopericytoma, occurred either in untreated controls or as single incidents in carcinogenic studies where no causal relationship could be established. Instances of transplantable hemangiopericytoma, adenocarcinoma of the breast, and cutaneous adnexal cystadenocarcinoma have not been reported previously in hamsters.
Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (&lt;12 months).
Authors: Christopher P. Venner, Joseph M. Connors, Heather J. Sutherland, John D. Shepherd, Linda Hamata, Yasser Abou Mourad, Michael J Barnett, Donna L. Forrest, Donna E. Hogge, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Janet Nitta, Maryse M Power, Cynthia L. Toze, Clayton Smith, Kevin Song
Journal: Blood (2009)
Light touch regulation may be most effective
Authors: Michael C Copeman
Journal: BMJ (2016)

The BMA says that the General Medical Council should be funded by the public rather than by doctors.1

Regulatory bodies such as the GMC and medical boards/councils in Australia have a first duty to protect the public. But the public may suffer if doctors—weary of increasing regulations or fearing career destroying inquisitions—shirk their obligations.

A regulatory body beholden to …
Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies
Authors: S. L. Allen, K. R. Rai, R. Elstrom, O. G. Negrea, C. M. Farber, R. Abbasi, N. Teoh, H. Horne, W. A. Wegener, D. M. Goldenberg
Journal: Journal of Clinical Oncology (2009)

8530 Background: Low IV doses of veltuzumab, a second-generation anti-CD20 monoclonal antibody with structure-function differences from chimeric rituximab, have shown clinical activity, thus justifying subcutaneous (SC) injections. Methods: A phase I/II study was initiated in patients (pts) with previously untreated or relapsed CD20+ indolent NHL or CLL who received 4 SC injections of veltuzumab 2 weeks apart at dose levels of 80, 160, or 320 mg. Efficacy was assessed by CT-based IWG (NHL) or hematology-based NCI/IWCLL (CLL) criteria 4 and 12 weeks later, with responding pts continuing follow-up. Other evaluations included AEs, safety laboratories, B-cell blood levels (CD19), serum veltuzumab levels, and human anti-veltuzumab antibody (HAHA) titers. Results: Nineteen pts (8M/11F, median age 63), including 14 NHL pts (11 follicular, 3 other indolent NHL; 5 treatment naive) most with stage III or IV disease (11/14) and 5 CLL pts (4 treatment naïve) all with Rai stage II or III disease, have now received SC veltuzumab at 80 mg (3 NHL, 3 CLL), 160 mg (9 NHL, 2 CLL) or 320 mg (2 NHL) dose levels. Pre-treatment with antihistamines or steroids has not been required, and SC veltuzumab was well tolerated with only mild, transient injection site reactions and tenderness. To date, all HAHA results have been negative. In NHL pts, SC veltuzumab demonstrates good bio-availability, with a slow release pattern over several days and depletion of circulating B cells starting after 1 st injection. Initial response information is currently available for 10 pts. For 7 NHL pts, 4 weeks after treatment with 80 or 160 mg doses, 2 pts had partial responses, 3 pts showed stable disease, and 2 pts had disease progression. For 3 CLL pts who received 80 mg doses, serum veltuzumab levels were lower, but all pts still achieved 65–75% decreases in circulating leukemic cells over the course of treatment. Conclusions: SC administration of veltuzumab is well tolerated, achieves slow but efficient delivery into the blood, and is pharmacologically active. The low doses currently evaluated in B-cell malignancies show evidence of therapeutic activity, achieving objective responses in NHL and notable reductions in circulating leukemic cells in CLL. [Table: see text]
Smoking Cessation
Authors: Manish S. Patel, Michael B. Steinberg
Journal: Annals of Internal Medicine (2016)

This issue provides a clinical overview of smoking cessation, focusing on health consequences of smoking, prevention of smoking-related disease, treatment, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of additional science writers and physician writers.
PD5-3-2: Prognostic value of the number of examined lymph nodes in totally resected Non-Small-Cell Lung Cancer
Authors: Jean-Yves Douillard, Jean-Sebastien Frenel, Loic Campion, Christine Sagan, Jean-Luc Michaud, Philippe Despins, Christian Perigaud, Antoine Mugniot, Laurent Cellerin
Journal: Journal of Thoracic Oncology (2007)
T Cell-Mediated Autoimmune Disease Due to Low-Affinity Crossreactivity to Common Microbial Peptides (DOI:10.1016/j.immuni.2009.01.009)
Authors: M Harkiolaki, S L Holmes, P Svendsen, J W Gregersen, L T Jensen, R McMahon, M A Friese, G van Boxel, R Etzensperger, J S Tzartos, K Kranc, S Sainsbury, K Harlos, Mellins, J Palace, M M Esiri, P A van der Merwe, E Y Jones, L Fugger
Journal: Immunity (2009)
First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).
Authors: Lecia V. Sequist, Jean-Charles Soria, Shirish M. Gadgeel, Heather A. Wakelee, D. Ross Camidge, Andrea Varga, Benjamin J. Solomon, Vassiliki Papadimitrakopoulou, Sarah S. Jaw-Tsai, Lisa Caunt, Paramjit Kaur, Lindsey Rolfe, Andrew R. Allen, Jonathan Wade Goldman
Journal: Journal of Clinical Oncology (2014)

8010^ Background: Efficacy of existing EGFR tyrosine kinase inhibitors (TKIs) in NSCLC is limited by emergence of the T790M mutation in approximately 60% of patients, and significant skin rash and diarrhea, caused by wild-type (WT)-EGFR inhibition. CO-1686 is an oral, covalent TKI that targets common activating EGFR mutations and T790M, while sparing WT-EGFR. Methods: This is a completed dose finding study in patients with EGFR mutated advanced NSCLC. Patients were previously treated with EGFR TKI and had a tumor biopsy in screening for central EGFR genotyping. CO-1686 was administered twice daily. Endpoints included safety, pharmacokinetics (PK), and efficacy. Results: As of 17thJanuary 2014, 88 patients were treated: 57 with CO-1686 free base (up to 900 mg BID); 31 with CO-1686 HBr (500 to1000 mg BID). 10 transitioned from free base to HBr. 63% were T790M+, median age 61 years, 77% female, 76% white, and 72% ECOG 1. Median number of previous therapies was 3 (1- 7); 40% had >1 prior line of EGFR TKI. PK of the CO-1686 HBr formulation was dose proportional with three times greater exposure than the equivalent free base dose. The dose limiting toxicity (DLT) rate at all doses was <33%. Related AEs (all grades) in ≥ 20% patients were: nausea (25%), fatigue (21%), impaired glucose tolerance/hyperglycemia (21%). Hyperglycemia was well managed with oral hypoglycemics and/or dose reduction. A recommended phase 2 dose of 750 mg BID has been selected. Nine T790M+ patients treated with 900 mg BID (free base) were evaluable for response; 6 (67%) achieved PRs, 2 (22%) achieved SD, one of whom subsequently achieved a PR after transition to CO-1686 HBr. Eight of nine progressed on EGFR TKI immediately before CO-1686. PRs have occurred among patients treated with CO-1686 HBr, however the majority of patients have not reached the first restaging. Efficacy data for at least 41 patients on CO-1686 HBr will be presented at the meeting. Conclusions: CO-1686 has demonstrated promising efficacy against T790M+ EGFR mutant NSCLC. CO-1686 HBr delivered higher exposures than free base and was equally well tolerated. Dose-related WT-driven diarrhea and rash has not been seen. The phase 2/3 program will open in 2014. Clinical trial information: NCT01526928.
The Components of Cigarette Smoke. I. Preliminary Studies&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Alvin I. Kosak, James S. Swinehart, David Taber
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article The Components of Cigarette Smoke. I. Preliminary Studies Get access Alvin I. Kosak, Alvin I. Kosak Institute of Industrial Medicine, New York University—Bellevue Medical Center, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar James S. Swinehart, James S. Swinehart Institute of Industrial Medicine, New York University—Bellevue Medical Center, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar David Taber David Taber Institute of Industrial Medicine, New York University—Bellevue Medical Center, New York, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 17, Issue 3, September 1956, Pages 375–389, https://doi.org/10.1093/jnci/17.3.375 Published: 01 September 1956 Article history Received: 05 March 1956 Published: 01 September 1956
Madonna II
Authors: M. Therese Southgate
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal